Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Radiothérapie par hypofraction pour le cancer du poumon non à petites cellules localement avancé

26 octobre 2026 mis à jour par: Dong Qian, Anhui Provincial Hospital

Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial

Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.

Aperçu de l'étude

Description détaillée

Trial title: Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase II clinical trial.

Trial objective: To explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.

Trial Design: To enroll 36 patients diagnosed with stage III locally advanced non-small cell lung cancer to receive hypofraction radiotherapy (18 patients receiving high dose of 60 (Gray, Gy) /15 (fraction, f) and 18 patients receiving low dose of 48Gy/12f) followed by 1-year maintenance of immune checkpoint inhibitors.

Inclusion Criteria: a. 18-70 years old; b. Eastern Cooperative Oncology Group (ECOG) 0-1; c. non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma; d. wild-type of driven genes; e. stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and Positron Emission Tomography (PET-CT); f. surgically unresectable or deny of surgery; g. signature of inform consent.

Exclusion Criteria: a. younger than 18 years old or older than 70 years old; b. ECOG>1; c. small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma; d. mutant type of driven genes; e. Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT; f. surgically resectable; g. no signature of inform consent.

Staging Examination before Radiotherapy: a. ECOG scoring. b. Cranial contrast MRI and PET-CT, or cranial contrast MRI (preferred), chest contrast CT, abdominal ultrasonography and bone scan. c. Bronchoscopy for centrally-located lung cancer. d. Staging examination is mandatory after inductive chemotherapy & chemotherapy with immunotherapy. e. Pulmonary function test.

Inductive therapy before radiotherapy: Chemotherapy or chemotherapy combined with immunotherapy is allowed as inductive therapy. Detailed regimen could refer to NCCN guidelines. Tyrosine kinase inhibitors are not allowed as inductive therapy.

Randomization: Patients would be randomly assigned to high dose group and low dose group using random number table method.

Radiotherapy CT simulation: 4-Dimensional CT (4D-CT) with intravenous contrast is recommended for simulation. Scan thickness should be less than 5 mm. Thermal mask or vacuum bag is recommended.

Target Delineation: Considering hypofraction and involved field irradiation (IFI), only Internal Tumor Volume (ITV) should be delineated without the need to delineate Clinical Tumor Volume (CTV).

Delineation of ITV: ITV should include pulmonary gross tumor and metastatic mediastinal lymph nodes. PET-CT registration with simulation CT is recommended for patients with obstructive atelectasis. For patients with suspected mediastinal lymph nodes, Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is recommended.

Production of Planning Tumor Volume (PTV):

Low-dose Arm (48Gy/12f) PTV: PTV is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.

High-dose Arm (60Gy/15f) PTV: Planning Tumor Volume (PTV) is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.

The protection of OAR was given higher priority than the prescription dose coverage of PTV. The dose to PTV in adjacent to or abutting esophagus and spinal cord could be compromised with the lowest coverage rate of 90%.

Dosimetric Limitation:

Total Lung: V20<23%, Dmean<13Gy, V5<50%. Spinal Cord: Dmax<40Gy. Heart:V42<15cc, Dmax<48.9Gy in high-dose arm, V36.6<15cc, Dmax<42.5Gy in low-dose arm.

Great Vessels: V57<10cc,Dmax<65Gy in high-dose arm, V55.7<10cc,Dmax<62.9Gy in low-dose arm.

Esophagus: V45<2.5cc in high-dose arm, V40<2.5 cc in low-dose arm. Proximal Bronchial Tree: V55.5<5cc, Dmax<65Gy in high-dose arm, V52<5cc, Dmax<59Gy in low-dose arm.

Branchial Plexus: V48<3cc, Dmax<52.5Gy in high-dose arm, V37<3cc, Dmax<43Gy in low-dose arm.

Treatment Implementation: Radiotherapy is implemented every day. Cone-beam CT should utilized every day to minimize set-up error.

Concurrent Chemotherapy:For patients who have received over 4 cycles of inductive chemotherapy with or without immunotherapy, no concurrent chemotherapy is needed. For patients who had not received induction therapy or less than 4 cycles of inductive chemotherapy with or without immunotherapy, concurrent chemotherapy is needed to ensure 4 cycles of chemotherapy. Adenocarcinoma: Pemetrexed combined with platinum is recommended. Squamous-cell lung cancer: Etoposide combined with platinum is recommended. One month after completion of radiotherapy, chest CT and abdominal ultrasonography should be undertaken. After exclusion of disease progression and grade 2 or more radiation-induced pneumonitis, consolidative immunotherapy should be started. Durvalumab maintenance for one year is recommended.

Follow-up: Patients should be follow-up every three months right after the completion of radiotherapy to 3 years after radiotherapy. Then follow-up every half year is allowed to 5 years after radiotherapy. After 5 years, follow-up every year is appropriate. In follow-up, chest CT and abdominal ultrasonography should be implemented. Cranial MRI should be performed every half year for patients with adenocarcinoma. Bone scan should be undertaken every year for all patients.

Primary Endpoint: Rate of radiation-induced pneumonitis, esophagitis, central hilar structure injury rate, hematologic toxicity (CTCAE V4.0).

Secondary Endpoint: Median overall survival, 2-year overall survival rate, Median progression-free survival, 2-year progression-free survival, Objective response rate, Complete response rate, Partial response rate (RECIST v1.1).

Type d'étude

Interventionnel

Inscription (Réel)

36

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Anhui
      • Hefei, Anhui, Chine
        • Anhui Provicial Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • 18-70 years old;
  • Eastern Cooperative Oncology Group (ECOG) 0-1;
  • Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
  • Wild-type of driven genes;
  • Stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
  • Surgically unresectable or deny of surgery;
  • Signature of inform consent.

Exclusion Criteria:

  • Younger than 18 years old or older than 70 years old;
  • ECOG>1;
  • Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
  • Mutant type of driven genes;
  • Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
  • Surgically resectable;
  • No signature of inform consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: High-dose Arm

Irradiation of 60Gy/15f is administered followed by one-year immunotherapy maintenance.

Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f with one-year immunotherapy maintenance.

Expérimental: Low-dose Arm

Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance.

Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/12f with one-year immunotherapy maintenance.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Rate of radiation-induced pneumonitis (CTCAE V4.0)
Délai: 1 to 2 years

Rate of radiation-induced pneumonitis (CTCAE V4.0)

1 to 2 years
Rate of radiation-induced esophagitis (CTCAE V4.0)
Délai: 1 to 2 years

Rate of radiation-induced esophagitis (CTCAE V4.0)

1 to 2 years
Rate of central hilar structure injury (CTCAE V4.0)
Délai: 1 to 2 years

Rate of central hilar structure injury (CTCAE V4.0)

1 to 2 years
Rate of hematologic toxicity
Délai: 1 to 2 years

Rate of hematologic toxicity

1 to 2 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Median overall survival (RECIST 1.1)
Délai: 1-2 year

Median overall survival (RECIST 1.1)

1-2 year
2-year overall survival rate (RECIST 1.1)
Délai: 2 year

2-year overall survival rate (RECIST 1.1)

2 year
Median progression-free survival (RECIST 1.1)
Délai: 1-2 year

Median progression-free survival (RECIST 1.1)

1-2 year
2-year progression-free survival rate (RECIST 1.1)
Délai: 2 year

2-year progression-free survival rate (RECIST 1.1)

2 year
Objective response rate
Délai: 3 months after radiotherapy

Objective response rate

3 months after radiotherapy
Complete response rate
Délai: 3 months after radiotherapy

Complete response rate

3 months after radiotherapy
Partial response rate
Délai: 3 months after radiotherapy

Partial response rate

3 months after radiotherapy

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 mars 2022

Achèvement primaire (Réel)

30 janvier 2024

Achèvement de l'étude (Réel)

30 janvier 2026

Dates d'inscription aux études

Première soumission

19 février 2022

Première soumission répondant aux critères de contrôle qualité

7 mars 2022

Première publication (Réel)

8 mars 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner